Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 palovarotene study in children with multiple osteochondromas
NL-OMON48469Phase 2Completed
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of palovarotene in osteochondromatosis (3 arms), sponsored by Clementia Pharmaceuticals Inc. Primary endpoint: Prevention of new osteochondromas. Started Mar 2019; status: completed.
02
Drugs
palovarotene
03
Conditions
osteochondromatosis
Beyond the preview
Go deeper on NL-OMON48469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48469.